Tags

Type your tag names separated by a space and hit enter

A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America.
Int J Clin Pract 2010; 64(9):1301-9IJ

Abstract

AIMS

The objective of this study was to evaluate the safety and efficacy of pregabalin at flexible doses of 150-600 mg/day in Latin American patients with neuropathic pain.

METHODS

A prospective, multicentre, open-label, non-comparative study included patients age >or= 18 years diagnosed with neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathic pain (PNP), or human immunodeficiency virus-related PNP. Eligible patients (N = 121) had a score of >or= 40 mm on the visual analogue scale and a daily pain rating scale (DPRS) score of >or= 4 throughout screening. Patients received flexible-dose pregabalin (150-600 mg/day) for 12 weeks, which included a 4-week dose-adjustment phase. The primary efficacy measure was change from baseline to end of treatment/last observation carried forward (EOT/LOCF) in weekly mean pain score on the DPRS. Secondary efficacy measures included pain, anxiety, sleep interference, treatment satisfaction and Patient and Clinician Global Impression of Change.

RESULTS

Pregabalin significantly reduced the weekly mean pain score on DPRS from baseline to EOT/LOCF [-3.8 (95% CI: -4.2 to -3.3); p < 0.0001]. Reductions from baseline to EOT/LOCF were observed for all secondary efficacy outcomes (p < 0.0001). Pain and sleep interference were significantly improved compared with baseline across all weeks of the study, as early as 1 week after initiation of pregabalin (p < 0.0001). The most common adverse events (AEs) were somnolence, dizziness, weight gain and peripheral oedema. Nine (7.4%) patients discontinued the study because of AEs and 25 (20.7%) temporarily stopped or reduced their pregabalin dose because of AEs.

CONCLUSIONS

Flexible-dose pregabalin (150-600 mg/day) significantly reduced pain and anxiety and improved sleep and was generally well tolerated in Latin American patients with neuropathic pain.

Authors+Show Affiliations

Centro de Investigacion Clinica del Pacifico, Acapulco, Mexico.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20487048

Citation

Xochilcal-Morales, M, et al. "A Prospective, Open-label, Multicentre Study of Pregabalin in the Treatment of Neuropathic Pain in Latin America." International Journal of Clinical Practice, vol. 64, no. 9, 2010, pp. 1301-9.
Xochilcal-Morales M, Castro EM, Guajardo-Rosas J, et al. A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. Int J Clin Pract. 2010;64(9):1301-9.
Xochilcal-Morales, M., Castro, E. M., Guajardo-Rosas, J., Obregón, T. N., Acevedo, J. C., Chucan, J. M., ... Vinueza, R. (2010). A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. International Journal of Clinical Practice, 64(9), pp. 1301-9. doi:10.1111/j.1742-1241.2010.02389.x.
Xochilcal-Morales M, et al. A Prospective, Open-label, Multicentre Study of Pregabalin in the Treatment of Neuropathic Pain in Latin America. Int J Clin Pract. 2010;64(9):1301-9. PubMed PMID: 20487048.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. AU - Xochilcal-Morales,M, AU - Castro,E M, AU - Guajardo-Rosas,J, AU - Obregón,T N, AU - Acevedo,J C, AU - Chucan,J M G, AU - Plancarte-Sanchez,R, AU - Davila,G, AU - Wajsbrot,D, AU - Guerrero,M, AU - Vinueza,R, Y1 - 2010/05/10/ PY - 2010/5/22/entrez PY - 2010/5/22/pubmed PY - 2011/8/2/medline SP - 1301 EP - 9 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 64 IS - 9 N2 - AIMS: The objective of this study was to evaluate the safety and efficacy of pregabalin at flexible doses of 150-600 mg/day in Latin American patients with neuropathic pain. METHODS: A prospective, multicentre, open-label, non-comparative study included patients age >or= 18 years diagnosed with neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathic pain (PNP), or human immunodeficiency virus-related PNP. Eligible patients (N = 121) had a score of >or= 40 mm on the visual analogue scale and a daily pain rating scale (DPRS) score of >or= 4 throughout screening. Patients received flexible-dose pregabalin (150-600 mg/day) for 12 weeks, which included a 4-week dose-adjustment phase. The primary efficacy measure was change from baseline to end of treatment/last observation carried forward (EOT/LOCF) in weekly mean pain score on the DPRS. Secondary efficacy measures included pain, anxiety, sleep interference, treatment satisfaction and Patient and Clinician Global Impression of Change. RESULTS: Pregabalin significantly reduced the weekly mean pain score on DPRS from baseline to EOT/LOCF [-3.8 (95% CI: -4.2 to -3.3); p < 0.0001]. Reductions from baseline to EOT/LOCF were observed for all secondary efficacy outcomes (p < 0.0001). Pain and sleep interference were significantly improved compared with baseline across all weeks of the study, as early as 1 week after initiation of pregabalin (p < 0.0001). The most common adverse events (AEs) were somnolence, dizziness, weight gain and peripheral oedema. Nine (7.4%) patients discontinued the study because of AEs and 25 (20.7%) temporarily stopped or reduced their pregabalin dose because of AEs. CONCLUSIONS: Flexible-dose pregabalin (150-600 mg/day) significantly reduced pain and anxiety and improved sleep and was generally well tolerated in Latin American patients with neuropathic pain. SN - 1742-1241 UR - https://www.unboundmedicine.com/medline/citation/20487048/A_prospective_open_label_multicentre_study_of_pregabalin_in_the_treatment_of_neuropathic_pain_in_Latin_America_ L2 - https://doi.org/10.1111/j.1742-1241.2010.02389.x DB - PRIME DP - Unbound Medicine ER -